Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 2
2010 6
2011 4
2012 14
2013 9
2014 6
2015 10
2016 14
2017 13
2018 21
2019 27
2020 30
2021 36
2022 52
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34969742

221 results

Results by year

Filters applied: . Clear all
Page 1
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G. Gramatzki D, et al. Eur J Cancer. 2021 Apr;147:84-94. doi: 10.1016/j.ejca.2021.01.014. Epub 2021 Feb 22. Eur J Cancer. 2021. PMID: 33631540 Free article.
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. Arita H, et al. Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2. Acta Neuropathol Commun. 2016. PMID: 27503138 Free PMC article.
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z, Geara F, Najjar M, Comair Y, Khoueiry-Zgheib N, Khoueiry P, Mahfouz R, Boulos FI, Kamar FG, Andraos T, Saadeh F, Kreidieh F, Abboud M, Skaf G, Assi HI. Ayoub Z, et al. Clin Neurol Neurosurg. 2019 Jul;182:92-97. doi: 10.1016/j.clineuro.2019.04.008. Epub 2019 Apr 29. Clin Neurol Neurosurg. 2019. PMID: 31108342
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. Nguyen HN, et al. Neuro Oncol. 2017 Mar 1;19(3):394-404. doi: 10.1093/neuonc/now189. Neuro Oncol. 2017. PMID: 27571882 Free PMC article.
221 results